The ranks of employees at Big Pharma companies are growing thinner, as this morning's news that AstraZeneca will lay off another 6,000 workers underscores with a vengeance. Analyst Manoj Ladwa says that the company's inability to forecast a sales jump this year--despite a rich pipeline of new therapies--is spooking investors. Our sister pub, FiercePharma, has more on the most recent cutbacks at AstraZeneca, which come on top of 7,600 job losses last year. Report l Report